Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy

Affiliations

• ¹ Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
• ² Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
• ³ Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
• ⁴ Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
• ⁵ Tennessee Valley Healthcare System, United States Department of Veterans Affairs, Nashville, Tennessee, USA.
• ⁶ Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.